Last reviewed · How we verify
diquafosol ophthalmic solution
At a glance
| Generic name | diquafosol ophthalmic solution |
|---|---|
| Also known as | HA |
| Sponsor | Santen Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Rebamipide Versus Diquafosol for Perioperative Dry Eye in Cataract Surgery (PHASE4)
- Rebamipide Versus Diquafosol and Cyclosporine for Perioperative Dry Eye in Cataract Surgery (PHASE4)
- 3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis (PHASE3)
- Effectiveness of Dry Eye Treatment With Diquafosol Sodium 3% After Phaco Surgery
- Compare the Clinical Efficacy of 3% Diquafosol and 0.1% Hyaluronic Acid in Patients With Dry Eye After LASIK (NA)
- Diquafosol vs Hyaluronic Acid for Diabetic Dry Eye (NA)
- Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients (PHASE3)
- Compare the Clinical Efficacy of 3% Diquafosol and 0.1% Hyaluronic Acid in Patients with Dry Eye After Trans-PRK (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |